MRNA News and Press, Moderna Inc. From 02/19/26

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 46 th Annual Healthcare Conference, on Tuesday, March 3 rd at 1:50pm ET Barclays 28 th Annual Global Hea...

2026-02-19 06:51:53 ET Listen below or on the go via Apple Podcasts and Spotify Carvana's (CVNA)Q4 profitability loses traction; shares crater more than 20%. (00:14) DoorDash ( DASH ) sees double-digit growth in orders, GOV; sets upbeat Q1 guidance. (01:3...

2026-02-18 18:30:00 ET The S&P 500 delivered strong returns for investors over the past three years as they piled into growth stocks in a number of fields, from technology to biotech and consumer goods. And they took a particular interest in players involved in artificial intelligen...

2026-02-18 14:13:52 ET More on Pfizer, Johnson & Johnson, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction ...

2026-02-18 13:35:32 ET Vaccine specialist Moderna (NASDAQ: MRNA) stock soared 5.5% through 12:55 p.m. ET Wednesday after The Wall Street Journal reported that the U.S. Food and Drug Administration will accept (note: "accept," but not automatically "approve") Moderna's applicatio...

2026-02-18 09:42:45 ET More on Moderna Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript Moderna, Inc. 2025 Q4 - Results - Earnings Call Presentation Moderna: FDA RTF Derails mRNA-1010 And Reignites The Sell Case Moderna gains as FDA backtracks and accept...

2026-02-18 07:50:16 ET More on Moderna Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript Moderna, Inc. 2025 Q4 - Results - Earnings Call Presentation Moderna: FDA RTF Derails mRNA-1010 And Reignites The Sell Case Changes to U.S. vaccine policy under RFK J...

Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to review Moderna has received a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026 CAMBRIDGE, MASSAC...

2026-02-17 09:31:00 ET In this podcast, Motley Fool contributors Tyler Crowe, Matt Frankel, and Jon Quast discuss: To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center . When you're ready to invest, check out this top 10 list of stocks t...

2026-02-17 07:15:07 ET Bernstein analyst issues MARKET PERFORM recommendation for MRNA on February 17, 2026 12:04PM ET. The previous analyst recommendation was Market Perform. MRNA was trading at $42.23 at issue of the analyst recommendation. The overall analyst consensu...